Methods for treating vertigo and motion sickness using descarboethoxyloratadine

Abstract

Methods for treating urinary incontinence, vertigo and motion sickness comprising administering a therapeutically effective amount of descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof.

What is claimed is:  
     
         1 . A method for treating urinary incontinence which comprises administering to a human in need of such treatment a therapeutically effective amount of DCL, or a pharmaceutically acceptable salt thereof.  
     
     
         2 . The method according to  claim 1 , wherein the amount of DCL, or a pharmaceutically acceptable salt thereof, administered is from about 0.1 mg to about 100 mg per day.  
     
     
         3 . The method according to  claim 2 , wherein the amount of DCL, or a pharmaceutically acceptable salt thereof, administered is from about 0.5 mg to about 50 mg per day.  
     
     
         4 . The method according to  claim 2 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by inhalation or by intravesical, parenteral, transdermal, rectal or oral administration.  
     
     
         5 . The method according to  claim 4 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by oral administration.  
     
     
         6 . The method according to  claim 4 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by transdermal administration.  
     
     
         7 . The method according to  claim 4 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by intravesical administration.  
     
     
         8 . A method for treating vertigo which comprises administering to a human in need of such treatment a therapeutically effective amount of DCL, or a pharmaceutically acceptable salt thereof.  
     
     
         9 . The method according to  claim 8 , wherein the amount of DCL, or a pharmaceutically acceptable salt thereof, administered is from about 0.1 mg to about 100 mg per day.  
     
     
         10 . The method according to  claim 9 , wherein the amount of DCL, or a pharmaceutically acceptable salt thereof, administered is from about 0.5 mg to about 50 mg per day.  
     
     
         11 . The method according to  claim 9 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by inhalation or by parenteral, transdermal, rectal or oral administration.  
     
     
         12 . The method according to  claim 11 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by oral administration.  
     
     
         13 . The method according to  claim 11 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by transdermal administration.  
     
     
         14 . The method according to  claim 8 , wherein the vertigo is a result of Meniere's disease.  
     
     
         15 . A method for treating motion sickness which comprises administering to a human in need of such treatment a therapeutically effective amount of DCL, or a pharmaceutically acceptable salt thereof.  
     
     
         16 . The method according to  claim 15 , wherein the amount of DCL, or a pharmaceutically acceptable salt thereof, administered is from about 0.1 mg to about 100 mg per day.  
     
     
         17 . The method according to  claim 16 , wherein the amount of DCL, or a pharmaceutically acceptable salt thereof, administered is from about 0.5 mg to about 50 mg per day.  
     
     
         18 . The method according to  claim 16 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by inhalation or by parenteral, transdermal, rectal or oral administration.  
     
     
         19 . The method according to  claim 18 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by oral administration.  
     
     
         20 . The method according to  claim 18 , wherein DCL, or a pharmaceutically acceptable salt thereof, is administered by transdermal administration.  
     
     
         21 . The method according to  claim 15 , wherein the motion sickness is space motion sickness.  
     
     
         22 . The method according to  claim 15 , wherein the motion sickness is sea sickness.  
     
     
         23 . A pharmaceutical composition having anticholinergic activity useful for treating urinary incontinence, vertigo and/or motion sickness which comprises a therapeutically effect amount of DCL, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.  
     
     
         24 . A pharmaceutical composition useful for treating motion sickness, comprising a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of ephedrine, and a pharmaceutically acceptable carrier.  
     
     
         25 . A pharmaceutical composition useful for treating motion sickness, comprising a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of a drug selected from the group consisting of amphetamines, amphetamine salts, and amphetamine analogs, and a pharmaceutically acceptable carrier.  
     
     
         26 . A pharmaceutical composition useful for treating motion sickness, comprising a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of an amphetamine agent, and a pharmaceutically acceptable carrier.  
     
     
         27 . A pharmaceutical composition useful for treating motion sickness, comprising a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of a psychostimulant, and a pharmaceutically acceptable carrier.  
     
     
         28 . A method for treating motion sickness comprising administering to a human in need of such treatment a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a decongestant.  
     
     
         29 . The method according to  claim 28  wherein the decongestant is pseudoephedrine.  
     
     
         30 . The method according to  claim 28  wherein the decongestant is phenylpropanolamine.  
     
     
         31 . A method for treating motion sickness comprising administering to a human in need of such treatment a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of ephedrine.  
     
     
         32 . A method for treating motion sickness comprising administering to a human in need of such treatment a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a drug selected from the group consisting of amphetamines, amphetamine salts, and amphetamine analogs.  
     
     
         33 . A method for treating motion sickness comprising administering to a human in need of such treatment a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of an amphetamine agent.  
     
     
         34 . A method for treating motion sickness comprising administering to a human in need of such treatment a therapeutically effective amount of DCL or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a psychostimulant.